Journal Information
Vol. 98. Issue 1.
Pages 59-67 (1 January 2023)
Visits
3980
Vol. 98. Issue 1.
Pages 59-67 (1 January 2023)
Original Article
Full text access
Systemic disease in leukocytoclastic vasculitis: a focus on direct immunofluorescence findings
Visits
3980
Sümeyre Seda Ertekinb,
Corresponding author
sertekin@ku.edu.tr

Corresponding author.
, Ayşe Esra Koku Aksua, Cem Leblebicic, Vefa Aslı Erdemird, Ozan Erdeme, Elif Bal Avcıa, Mehmet Salih Güreld
a Department of Dermatology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
b Department of Dermatology, Koç University School of Medicine, Istanbul, Turkey
c Department of Pathology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
d Department of Dermatology, Göztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey
e Department of Dermatology, Başakşehir Çam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract
Background

Direct immunofluorescence (DIF) panels are usually ordered for clinically suspected cutaneous vasculitis, but their positivity rate is variable, and their prognostic significance is not clear to date.

Objective

The study aims to investigate the systemic involvement rate in leukocytoclastic vasculitis (LCV) patients and the potential clinical and laboratory associations with systemic involvement, including DIF findings.

Methods

A retrospective study of patients with histopathologically proven cutaneous LCV examined in the dermatology department between 2013 and 2017 was performed.

Results

Of the 81 patients (mean age, 50.6 years), 42 (52%) were male. The mean time between the appearance of skin lesions and biopsy was 23.1 days, ranging from 2 to 180 days. DIF showed overall positivity of 90.1%, and C3 was the most frequent immunoreactant (82.7%). Any kind of extracutaneous involvement was present in 47 (58%) of patients, with renal involvement being the most frequent (53.1%), followed by articular (18.5%) and gastrointestinal (11.1%) involvement. The presence of renal disease was associated with the detection of IgG in the lesional skin (p = 0.017), and with the absence of IgM in the lesional skin (p = 0.032). There was a significant association between C3 deposition and joint involvement (p = 0.05).

Study limitations

This is a single-center study with a retrospective design.

Conclusion

DIF seems to be a useful ancillary diagnostic tool in the evaluation of cutaneous vasculitis, but the relationship between DIF findings and systemic involvement needs to be further elucidated due to contradictory data in the current literature.

Keywords:
Fluorescent antibody technique, direct
Immunoglobulin M
Immunoglobulin G
Systemic vasculitis
Vasculitis, leukocytoclastic, cutaneous
Full Text
Introduction

Leukocytoclastic vasculitis is a histopathologic term that defines small-vessel vasculitis in which the perivascular inflammatory infiltrate is composed of neutrophils.1 This term is typically used for skin-predominant vasculitis, which most commonly presents with palpable or nonpalpable purpura on the lower extremities. LCV is often idiopathic in nature but may be associated with some underlying conditions, such as infections, exposure to certain medications, connective tissue disorders, or neoplasms.2 Leukocytoclastic vasculitis can be limited to the skin, but extracutaneous involvement (renal, gastrointestinal, articular, etc.) is not rare and was reported to be present in 12.5% to 57% of patients with LCV in different studies.3–9

LCV is often mediated by immune complex deposition in the postcapillary venule walls and by activation of the complement system, which results in neutrophil recruitment and finally, destruction of the vessel wall.10 Due to the immunological nature of its pathophysiology, LCV has been subject to Direct Immunofluorescence (DIF) studies for many years, and it is recommended to be performed, whenever possible, in the setting of LCV.11 DIF can aid in the determination of some specific subtypes of LCV (for example IgA vasculitis) and the identification of the possible underlying etiologies.6,12,13 Furthermore, recently some studies tried to determine its possible prognostic significance in LCV, by relating results of DIF examination with specific systemic involvement. The presence of IgM deposition of the vessel walls was associated with renal involvement in some studies,14,15 but this finding couldn’t be confirmed by other studies.6,7,16–18 The prognostic role of DIF studies in LCV is still controversial and currently lacks specificity.19

In this study, we aimed to evaluate the potential association between the skin DIF results and extracutaneous involvement in adult LCV patients.

MethodsPatient selection

A retrospective review of adult patients (age ≥ 16 years) with histopathologically proven cutaneous leukocytoclastic vasculitis examined in the dermatology department between 2013 and 2017 was performed. Histopathologic diagnosis of LCV was rendered based on the presence of two out of three of the following criteria: (1) Fibrinoid necrosis, (2) Perivascular neutrophilic infiltrate, (3) Disruption and/or destruction of vessel walls by the inflammatory infiltrate.12 All of the patients had concomitant DIF analysis, as DIF examination has been routinely performed in the studied clinic for all cases with suspected cutaneous vasculitis since the beginning of 2013. All of the patients had a Complete Blood Test (CBC), serum creatinine level, and urinalysis at the time of their first admission.

Clinical and laboratory investigations

Medical data abstracted from patients’ records included lesion distribution, the severity of lesions, suspected etiologies, duration of the rash, presence, or absence of any kind of systemic involvement, laboratory findings, and pathology reports (including DIF findings). The severe presentation was defined as presenting vesicles, blisters, ulcers, and/or skin necrosis accompanying palpable/nonpalpable purpuric lesions.

The criteria used for systemic involvement were similar to those used in previous studies.14–16 Renal involvement was determined through proteinuria, microscopic or macroscopic hematuria, creatinine elevation above baseline, and/or renal involvement confirmed by histological studies. Patients were considered to have Gastrointestinal (GI) tract involvement in the presence of colic-style abdominal pain, hematochezia, and/or positive Fecal Occult Blood Test (FOBT). The existence of arthritis or arthralgia was assessed as joint involvement, only if the onset was recent and if there was no alternative explanation.

Information regarding the following laboratory tests was recorded, whenever they were available: Serological determination for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV); Erythrocyte Sedimentation Rate (ESR); Complement Study (C3, C4); determinations of rheumatoid factor, Antinuclear Antibody (ANA), Antineutrophil Cytoplasmic Antibody (ANCA), cryoglobulins and Fecal Occult Blood Test (FOBT).

Statistical analyses

Statistical analyses were performed with IBM SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Data for qualitative variables were presented as a number (percentage), and data for quantitative variables as mean ± standard deviation or median (minimum-maximum) as appropriate. Pearson’s Chi-Square test was carried out for the comparison of categorical variables; a p-value <0.05 was considered statistically significant.

ResultsDemographic and clinical characteristics of the patients

From 2013 to 2017, 81 consecutive individuals (39 females, 42 males) were diagnosed as LCV by histopathology in the present study’s hospital, and DIF was performed in all those patients. The demographic and clinical characteristics of the population are summarized in Table 1. The age of the patients ranged from 16 to 90 years with a mean age of 50.6 years. The mean duration of rash from the reported onset to the time of biopsy was 23.1 days (range 2‒180 days). The commonest site was the lower extremity which was involved in all patients (n = 81, 100%). Thirty-seven (45.7%) of the cases had lesions above the waist, which were distributed on the upper extremities (n = 32, 39.5%), trunk (n = 22, 27.2%) and head and neck (n = 2, 2.5%). While most of the patients presented with petechiae, purpura, or macules, 35 (43.2%) patients showed severe skin involvement in the form of bullae, ulcers, and/or necrosis.

Table 1.

Demographic and clinical findings of the patients.

Characteristics  Patients (n = 81) n (%) 
Age, mean ± SD; median (min.‒max.), years  50.6 ± 20.3; 52 (16–90) 
Sex   
Female  39 (48.1) 
Male  42 (51.8) 
Duration of rash to biopsy, mean ± SD; median (min.‒max.), days  23.1 ± 34.4; 10 (2–180) 
Site of involvementa   
Head & neck  2 (2.5) 
Trunk  22 (27.2) 
Upper extremities  32 (39.5) 
Arm  29 (35.8) 
Hand  22 (27.2) 
Lower extremities  81 (100) 
Thigh  40 (49.4) 
Leg  81 (100) 
Foot  76 (93.8) 
Skin lesions above waist  37 (45.7) 
Severe cutaneous involvement (bullae, ulcer, necrosis)  35 (43.2) 
Suspected etiologies   
Idiopathic  48 (59.3) 
Concomitant infection + antibiotic use  13 (16) 
Infection  9 (11.1) 
Neoplasms  6 (7.4) 
Drug exposure  5 (6.2) 
Systemic involvement, any  47 (58) 
Renal  43 (53.1) 
Joint  15 (18.5) 
Gastrointestinal  9 (11.1) 
Peripheric nerve  1 (1.2) 
a

Total percentage may exceed 100% because of multiple involvement.

The most common underlying cause was concomitant infection and systemic antibiotic use (16%), followed by infection (11.1%), neoplasms (7.4%), and drug exposure (6.2%). No etiological association or predisposing factors could be identified in 48 (56.3%) patients which were classified as idiopathic LCV.

Any kind of extracutaneous involvement was present in 47 (58.0%) of patients. Articular involvement was noted in 15 patients (18.5%), renal involvement in 43 (53.1%), and gastrointestinal involvement was noted in 9 (11.1%). Only one patient (1.2%) had neurologic involvement in the form of peripheral neuropathy.

Laboratory and immunofluorescence findings

The most common laboratory alteration was elevated ESR, which was observed in 45 out of 64 patients (70.3%). Leukocytosis (WBC > 11.0 × 10^9/L) was detected only in 24.7% of patients. All laboratory and immunofluorescence findings were summarized in Table 2. Renal involvement was detected as proteinuria in 31 of 81 patients (38.3%) and microscopic or macroscopic hematuria in 42 patients (51.9%). In 30 cases (37%), proteinuria and hematuria were detected together. Only 11 patients (13.6%) had serum creatinine elevation above baseline. Patients with renal involvement were referred to nephrology for follow-up. GI tract involvement was detected as FOBT positivity in 6 of 57 patients (10.5%).

Table 2.

Laboratory and direct immunofluorescence of skin lesion characteristics of the patients.

Characteristics  Patients n/total (%) 
High ESR  45/64 (70.3) 
WBC alteration (leukocytosis)  20/81 (24.7) 
Renal dysfunction  43/81 (53.1) 
Proteinuria  31/81 (38.3) 
Hematuria  42/81 (51.9) 
Hematuria + proteinuria  30/81 (37) 
Serum creatinine elevation above baseline  11/81 (13.6) 
Positive fecal occult blood test  6/57 (10.5) 
Positive ANA  4/50 (8) 
Low C3/C4  4/45 (8.9) 
Positive rheumatoid factor  3/35 (8.6) 
Positive ANCA  1/41 (2.4) 
Cryoglobulinemia  2/32 (6.3) 
HIV (+)  1/44 (2.3) 
Hepatitis B (+)  1/46 (2.2) 
Hepatitis C (+)  0/46 (0) 
Positive immunoreactant, any  73/81 (90.1) 
IgA  35/81 (43.2) 
IgG  18/81 (22.2) 
IgM  19/81 (23.5) 
C3  67/81 (82.7) 
Fibrinogen  59/81 (72.8) 

ESR, Erythrocyte Sedimentation Rate; WBC, White Blood Cells; C, Complement, ANA, Anti-Nuclear Antibody; ANCA, Antineutrophil Cytoplasmic Antibodies; HIV, Human Immunodeficiency Virus; Ig, Immunoglobulin.

DIF was positive in 73 patients (90.1%), with C3 being the most common immunoreaction deposited in the wall of blood vessels (82.7%), followed by fibrinogen (72.8%), IgA (43.2%), IgM (23.5%) and IgG (22.2%). Table 3 shows the relation of DIF positivity with the duration of rash from the reported onset to the time of biopsy. Although statistically not significant; the DIF positivity rate was higher in biopsies performed within 7 days (95.8%), compared to biopsies performed between 7‒28 days (89.5%) and later than 28 days (84.2%) (p = 0.440).

Table 3.

Relation of time of biopsy and direct immunofluorescence positivity.

Timing of biopsyDIF positivityp-value
Yes, n (%)  No, n (%) 
< 7 days  23 (95.8%)  1 (4.2%)  0.440
7–28 days  34 (89.5%)  4 (10.5%) 
> 28 days  16 (84.2%)  3 (15.8%) 
Association between some clinical, laboratory and immunofluorescence parameters and systemic involvement

The presence of lesions above the waist (upper extremities, trunk, face) was found to be associated with renal (p = 0.017) and GI involvement (p = 0.04), but not with joint involvement. Severe cutaneous involvement in the form of bullae, ulcers, and/or necrosis was not found to be a significant predictor of the renal, gastrointestinal tract, or joint involvement disease. We found no relationship between the presence of an etiological factor (infection, drug exposure, and/or malignancy) and any kind of systemic involvement (Table 4).

Table 4.

Association between clinical, laboratory and immunofluorescence parameters and systemic involvement.

CharacteristicsRenal involvementp-valueJoint involvementp-valueGIS involvementp-value
No(n = 38)  Yes(n = 43)  No(n = 66)  Yes(n = 15)  No(n = 72)  Yes(n = 9) 
Lesions above waist  12 (31.6)  25 (58.1)  0.017  28 (42.4)  9 (60)  0.217  30 (41.7)  7 (77.8)  0.040 
Severe cutaneous involvement (bullae, ulcer, necrosis)  13 (34.2)  22 (51.2)  0.124  29 (43.9)  6 (40)  0.781  30 (41.7)  5 (55.6)  0.428 
Presence of etiologic factor  17 (44.7)  17 (39.5)  0.638  26 (39.4)  8 (53.3)  0.323  30 (41.7)  4 (44.4)  0.874 
ESR alteration (n = 64)  19/31 (61.3)  25/33 (75.8)  0.212  33/52 (63.5)  11/12 (91.7)  0.057  38/56 (67.9)  6/8 (75)  0.683 
WBC alteration (leukocytosis)  6 (15.8)  14 (32.6)  0.081  15 (22.7)  5 (33.3)  0.390  17 (23.6)  3 (33.3)  0.524 
Positive immunoreactant, anya  35 (92.1)  38 (88.4)  0.574  58 (87.9)  15 (100)  0.340  67 (93.1)  6 (66.7)  0.041 
IgA  16 (42.1)  19 (44.2)  0.850  29 (43.9)  6 (40)  0.781  33 (45.8)  2 (22.2)  0.178 
IgG  4 (10.5)  14 (32.6)  0.017  12 (18.2)  6 (40)  0.067  17 (23.6)  1 (11.1)  0.395 
IgM  13 (34.2)  6 (14)  0.032  16 (24.2)  3 (20)  0.726  18 (25)  1 (11.1)  0.354 
C3  32 (84.2)  35 (81.4)  0.738  52 (78.8)  15 (100)  0.050  61 (84.7)  6 (66.7)  0.182 
Fibrinogen  30 (78.9)  29 (67.4)  0.245  47 (71.2)  12 (80)  0.490  53 (73.6)  6 (66.7)  0.659 

GIS, Gastrointestinal System; ESR, Erythrocyte Sedimentation Rate; WBC, White Blood Cells; C, Complement; Ig, Immunoglobulin.

a

Total percentage may exceed 100% because of multiple positivity.

There was no link between ESR alteration or leukocytosis and any kind of systemic involvement.

The presence of renal disease was associated with the detection of IgG in the lesional skin (p = 0.017), whereas the absence of IgM in the lesional skin (p = 0.032). There was a significant association between C3 deposition and joint involvement (p = 0.05). Apart from these, there was no association between the existence or absence of any immunoreaction and systemic involvement (Table 4).

Discussion

The evaluation of the patient with cutaneous lesions suspicious of vasculitis should include a detailed anamnesis and physical examinations with some specific laboratory tests not to miss a potential systemic involvement. Treatment approach and follow-up schedules vary depending on whether there is systemic involvement or not. In the present study, we have retrospectively searched for the systemic involvement rate in LCV patients and potential clinical and laboratory associations with systemic involvement, including DIF findings.

Systemic involvement was documented in 58% of all LCVs in the present study, which is in the upper range of previous reports: from 12.5% to 57% depending on the design of studies and the inclusion criteria of the patients.4,6–9 Joint involvement is usually reported to be the most frequent site of involvement, followed by renal and GI involvement.8,9 However, in this study, renal involvement was the most frequent systemic involvement. The relatively lower renal involvement rates in some other studies could be explained by the strict criteria they used for defining renal involvement, such as the necessity of histological-proven nephropathy.6

In most centers, DIF analysis is routinely performed in clinically suspected cases of cutaneous vasculitis. Small vessel vasculitis of the skin is mediated by immune complex deposition in the post-capillary venules. Circulating antigens due to drug exposure, infectious agents, connective tissue disease, or neoplasia are bound by antibodies, forming immune complexes, which then can be detected by direct immunofluorescence studies.20 The overall positivity rate of DIF in LCV cases varies in the literature from 39% to as high as 97%.17,21–24 In the present study, we found positive DIF for at least one immunoglobulins and/or complement and/or fibrinogen in 90.1% of the cases, compatible with the previous reports. The most common positive immunoreactant was C3, and the most common positive immunoglobulin was IgA. Regarding the positivity pattern, the present findings are in line with the current literature where C3 is the most common immunoreaction in almost all of the studies.6,17,22,25,26 Although the exact reason for this finding is not known, we can assume that it may be related to the timing of the skin biopsy as immunoglobulins tend to be disappearing faster compared to the complement, and C3 is known to be deposited in relatively later lesions of vasculitis.9,27

For an ideal evolution of DIF specimens, it is advised to choose a newer lesion, between 8 h and 24 h of age, to biopsy. It has been shown that the DIF positivity rates drop concerningly in older lesions, especially if they are >1 week old. In a study reported by Nandeesh et al., the DIF positivity rate was 85% if the biopsy was taken within one week of onset of symptoms, whereas it was only 14% if was taken after a week.22 In the present study DIF positivity rate was found to be higher if the samples were taken early during the course of the disease (95.8% for <7 days vs. 84.2% for >28 days), however, the difference was not as obvious as it is in the report of Nandeesh et al. But these results should be interpreted carefully, because in the report of Nandeesh et al., as in ours, the exact age of each individual lesion that was biopsied could not be detected, due to retrospective design of both studies. Instead, the time from the appearance of the first lesion to the biopsy was included in the analyses. In the present clinic, we always tend to find a fresh appearing individual skin lesion to biopsy, even in the setting of a longer disease course. We believe that the results of the present study are interesting, as it showed that even if the vasculitic skin rash is present for a longer period of time, DIF can still be positive and diagnostic, especially if we manage to find a fresh appearing lesion to biopsy.

The most frequent etiological causes of LCV are infections, drug exposure, neoplasm, and connective tissue disorders, while almost half of the cases are idiopathic in which no etiological cause can be determined.28–30 Consistent with the previous reports, in the present study, idiopathic cases ranked at the top, at 59.3%, and concomitant infections and antibiotic use were second, at 16%.

We have investigated if some clinical features could be a clue for systemic involvement in patients with LCV. In some previous reports, presenting cutaneous vasculitic lesions above the waist has been found to point out renal or gastrointestinal involvement in HSP patients.20,27,31 Severe cutaneous involvement with vesiculobullous lesions was found to be indicative of systemic involvement in some reports, but this correlation could not be validated in some others.14,28,32 In the present study, the presence of lesions above the waist was significantly associated with both renal and GI involvement, thus emphasizing the importance of a thorough clinical exam. However, severe cutaneous involvement (in form of bullae, ulcers, and/or necrosis) was not associated with systemic involvement. In other words, in the present study systemic involvement was not related to the severity or type of skin lesions, but to their localization.

For patients diagnosed with LCV, any laboratory changes possibly indicating systemic involvement are important. In the literature, high ESR was reported to be the most frequently seen laboratory finding among LCV patients.4,26,28 In some of those studies, high ESR was associated with systemic involvement, whereas in some others no such relationship could be found. Similarly, high ESR was the most common laboratory alteration in the present study, being present in 70.3% of patients, and neither it nor leukocytosis was related to systemic involvement.

Numerous studies have attempted to correlate DIF findings with systemic disease in patients with cutaneous vasculitis. The findings of the previous studies related to DIF findings in LCV are summarized in Table 5.6,7,9,17,23,26 The presence of IgA in the lesional skin of LCV patients was associated with renal involvement in two different case series.7,17 However, Takatu et al. couldn’t revalidate this finding, but instead, they found that C3 deposition at the blood vessel wall was related to renal involvement.6 In some other reports, no association was found between any extracutaneous involvement and DIF results.9,26 In the present study, the presence of IgG in lesional skin was associated with renal involvement and the presence of C3 with joint involvement. Furthermore, the absence of IgM was associated with renal involvement. Unlike ours, in some studies which only included HSP patients, the authors concluded that there was a positive correlation between IgM deposition and renal involvement.14,15

Table 5.

Findings of previous studies about the relationship between DIF findings and systemic involvement in LCV patients.

  Number of included patients  Systemic involvement rate (any type)  Renal involvement rate  Gastrointestinal involvement rate  Joint involvement rate  DIF positivity rate  Most common positive immunoreactant in DIF examination  Correlation of DIF findings with systemic involvement 
Sais et al.26  160  20%* (*Other than the joint involvement)  N/A  N/A  N/A  84.3%  C3, followed by IgA  No correlation was found between DIF and systemic involvement 
Barnadas et al.17  50  N/A  50%  N/A  N/A  92%  C3, followed by IgA  IgA deposition was related to renal involvement 
Alalwani et al.7  88  50.9%  21.7%  15.1%  34.9%  70.5%  IgA was the most common Immunoglobulin (no info about C3)  IgA deposition was related to renal and gastrointestinal involvement. 
Takatu et al.6  282  12.5%  N/A  N/A  N/A  70,2%  C3, followed by IgA  C3 deposition was related to hematuria and renal involvement 
Gülseren et al.9  68  N/A  52%  28%  57%  53%  C3, followed by IgA  No association was found between DIF results and extracutaneous involvement 
Lath et al.23  198  29.4%  N/A  10%  18.8%  60%  IgA, followed by C3  N/A 
Present study, 20218158%53.1%11.1%18.5%90.1%C3, followed by IgAIgG deposition was associated with renal involvement. 
Absence of IgM deposition was associated with renal involvement. 
C3 deposition was associated with joint involvement. 

N/A, Not Available: It is used when related information was not found in the study.

Limitations of this study include a single-center study with a relatively small sample size, though comparable to other DIF-related studies in LCV. Due to the retrospective design of the study not all patients had exactly the same work-up performed, which may lead to an overestimation of idiopathic cases in the present series. Another important limitation is the lack of long-term follow-up information on patients with systemic involvement, so their prognosis remains unknown.

Conclusion

In conclusion, DIF seems to be a useful ancillary diagnostic tool in the evaluation of cutaneous vasculitis, being positive in more than 90% of all patients. Systemic involvement was not rare and was detected in 58% of patients. Deposition of IgG and absence of IgM were associated with renal involvement, whereas deposition of C3 was associated with joint involvement. In light of the results of this study and contradictory data in the literature, we believe that the potential relationship between DIF findings and systemic involvement needs to be further elucidated, as differences in the results may generate discordant interpretations. Distribution of the skin lesions above the waist was a reliable indicator of renal and gastrointestinal disease in adults with LCV, thus emphasizing the importance of a thorough clinical exam.

IRB approval status

The research protocol received approval from the Research Ethics Committee of the Istanbul Training and Research Hospital (IRB number: IEAH-KAEK-2830).

Financial support

None declared.

Authors' contributions

Sümeyre Seda Ertekin: Study concept and design; data collection, or analysis and interpretation of data; statistical analysis; writing of the manuscript or critical review of important intellectual content; effective participation in the research guidance; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; final approval of the final version of the manuscript.

Ayşe Esra Koku Aksu: Study concept and design; writing of the manuscript or critical review of important intellectual content; effective participation in the research guidance; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; final approval of the final version of the manuscript.

Cem Leblebici: Study concept and design; data collection, or analysis and interpretation of data, effective participation in the research guidance; final approval of the final version of the manuscript.

Vefa Aslı Erdemir: Writing of the manuscript or critical review of important intellectual content; effective participation in the research guidance; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; final approval of the final version of the manuscript.

Ozan Erdem: Data collection, or analysis and interpretation of data; statistical analysis; writing of the manuscript or critical review of important intellectual content; critical review of the literature; final approval of the final version of the manuscript.

Elif Bal Avcı: Data collection, or analysis and interpretation of data; critical review of the literature; final approval of the final version of the manuscript.

Mehmet Salih Gürel: Study concept and design; effective participation in the research guidance; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; final approval of the final version of the manuscript.

Conflicts of interest

None declared.

References
[1]
J.C. Jennette, R.J. Falk, P.A. Bacon, N. Basu, M.C. Cid, F. Ferrario, et al.
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.
Arthritis Rheum, 65 (2013), pp. 1-11
[2]
M.R. Goeser, V. Laniosz, D.A. Wetter.
A practical approach to the diagnosis, evaluation, and management of cutaneous small-vessel vasculitis.
Am J Clin Dermatol, 15 (2014), pp. 299-306
[3]
A. Arora, D.A. Wetter, T.M. Gonzalez-Santiago, M.D. Davis, C.M. Lohse.
Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in Olmsted County, Minnesota.
Mayo Clin Proc, 89 (2014), pp. 1515-1524
[4]
Y.J. Tai, A.H. Chong, R.A. Williams, S. Cumming, R.I. Kelly.
Retrospective analysis of adult patients with cutaneous leukocytoclastic vasculitis.
Australas J Dermatol, 47 (2006), pp. 92-96
[5]
E. Ekenstam, J.P. Callen.
Cutaneous leukocytoclastic vasculitis. Clinical and laboratory features of 82 patients seen in private practice.
Arch Dermatol, 120 (1984), pp. 484-489
[6]
C.M. Takatu, A.P.R. Heringer, V. Aoki, N.Y.S. Valente, P.C. de Faria Sanchez, J.F. de Carvalho, et al.
Clinicopathologic correlation of 282 leukocytoclastic vasculitis cases in a tertiary hospital: a focus on direct immunofluorescence findings at the blood vessel wall.
Immunol Res, 65 (2017), pp. 395-401
[7]
M. Alalwani, S.D. Billings, C.E. Gota.
Clinical significance of immunoglobulin deposition in leukocytoclastic vasculitis: a 5-year retrospective study of 88 patients at cleveland clinic.
Am J Dermatopathol, 36 (2014), pp. 723-729
[8]
K. Bouiller, S. Audia, H. Devilliers, E. Collet, M.H. Aubriot, V. Leguy-Seguin, et al.
Etiologies and prognostic factors of leukocytoclastic vasculitis with skin involvement: A retrospective study in 112 patients.
Medicine (Baltimore), 95 (2016),
[9]
D. Gulseren, E. Erbağcı, Ö Gököz, N. Atakan.
The relationship between direct immunofluorescence findings and clinical and laboratory parameters in patients with cutaneous small vessel vasculitis.
Turkish Journal of Dermatology, 14 (2020), pp. 42-47
[10]
T. Lotti, I. Ghersetich, C. Comacchi, J.L. Jorizzo.
Cutaneous small-vessel vasculitis.
J Am Acad Dermatol, 39 (1998), pp. 667-687
[11]
R.W. Minz, S. Chhabra, S. Singh, B.D. Radotra, B. Kumar.
Direct immunofluorescence of skin biopsy: perspective of an immunopathologist.
Indian J Dermatol Venereol Leprol, 76 (2010), pp. 150-157
[12]
J.A. Carlson, B.T. Ng, K.R. Chen.
Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis.
Am J Dermatopathol, 27 (2005), pp. 504-528
[13]
J.A. Carlson.
The histological assessment of cutaneous vasculitis.
Histopathology, 56 (2010), pp. 3-23
[14]
A.A. Belli, E. Dervis.
The correlation between cutaneous IgM deposition and renal involvement in adult patients with Henoch-Schönlein purpura.
Eur J Dermatol, 24 (2014), pp. 81-84
[15]
S. Takeuchi, Y. Soma, T. Kawakami.
IgM in lesional skin of adults with Henoch-Schönlein purpura is an indication of renal involvement.
J Am Acad Dermatol, 63 (2010), pp. 1026-1029
[16]
T.J. Poterucha, D.A. Wetter, L.E. Gibson, M.J. Camilleri, C.M. Lohse.
Correlates of systemic disease in adult Henoch-Schönlein purpura: a retrospective study of direct immunofluorescence and skin lesion distribution in 87 patients at Mayo Clinic.
J Am Acad Dermatol, 67 (2012), pp. 612-616
[17]
M.A. Barnadas, E. Pérez, I. Gich, J.M. Llobet, J. Ballarín, F. Calero, et al.
Diagnostic, prognostic and pathogenic value of the direct immunofluorescence test in cutaneous leukocytoclastic vasculitis.
Int J Dermatol, 43 (2004), pp. 19-26
[18]
A. Tirado-Sánchez, A. Bonifaz, R.M. Ponce-Olivera.
IgM in lesional skin is indicative of renal involvement in adults with Henoch-Schönlein purpura but not children.
J Am Acad Dermatol, 64 (2011), pp. 1183-1184
[19]
R.H. Kim, N.K. Brinster.
Practical Direct Immunofluorescence.
Am J Dermatopathol, 42 (2020), pp. 75-85
[20]
C. Demirkesen.
Approach to cutaneous vasculitides with special emphasis on small vessel vasculitis: histopathology and direct immunofluorescence.
Curr Opin Rheumatol, 29 (2017), pp. 39-44
[21]
M.H. Grunwald, I. Avinoach, B. Amichai, S. Halevy.
Leukocytoclastic vasculitis-correlation between different histologic stages and direct immunofluorescence results.
Int J Dermatol, 36 (1997), pp. 349-352
[22]
B. Nandeesh, R. Tirumalae.
Direct immunofluorescence in cutaneous vasculitis: experience from a referral hospital in India.
Indian J Dermatol, 58 (2013), pp. 22-25
[23]
K. Lath, D. Chatterjee, U.N. Saikia, B. Saikia, R. Minz, D. De, et al.
Role of Direct Immunofluorescence in Cutaneous Small-Vessel Vasculitis: Experience From a Tertiary Center.
Am J Dermatopathol, 40 (2018), pp. 661-666
[24]
M. Poornimambaa, N. Asokan, J. Augustine.
Utility of Direct Immunofluorescence in the Diagnosis of Small Vessel Vasculitis of the Skin: A Cross-Sectional Study.
Indian Dermatology Online Journal, 8 (2017), pp. 515-517
[25]
P. Khetan, G. Sethuraman, B.K. Khaitan, V.K. Sharma, R. Gupta, A.K. Dinda, et al.
An aetiological & clinicopathological study on cutaneous vasculitis.
Indian J Med Res, 135 (2012), pp. 107-113
[26]
G. Sais, A. Vidaller, A. Jucglà, O. Servitje, E. Condom, J. Peyri.
Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients.
Arch Dermatol, 134 (1998), pp. 309-315
[27]
E.F. Johnson, J.S. Lehman, D.A. Wetter, C.M. Lohse, M.M. Tollefson.
Henoch-Schönlein purpura and systemic disease in children: retrospective study of clinical findings, histopathology and direct immunofluorescence in 34 paediatric patients.
Br J Dermatol, 172 (2015), pp. 1358-1363
[28]
A.U. Cakiter, O.S. Kucuk, D.B. Ozkaya, B. Topukcu, N. Onsun.
Demographic characteristics, aetiology, and assessment of treatment options in leukocytoclastic vasculitis.
Postepy dermatologii i alergologii, 34 (2017), pp. 104-109
[29]
V.M. Martinez-Taboada, R. Blanco, M. Garcia-Fuentes, V. Rodriguez-Valverde.
Clinical features and outcome of 95 patients with hypersensitivity vasculitis.
Am J Med, 102 (1997), pp. 186-191
[30]
S.J. Jessop.
Cutaneous leucocytoclastic vasculitis: a clinical and aetiological study.
Br J Rheumatol, 34 (1995), pp. 942-945
[31]
E. Tancrede-Bohin, S. Ochonisky, M.D. Vignon-Pennamen, B. Flageul, P. Morel, M. Rybojad.
Schönlein-Henoch purpura in adult patients. Predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases.
Arch Dermatol, 133 (1997), pp. 438-442
[32]
H.W. Su, C.Y. Chen, Y.H. Chiou.
Hemorrhagic bullous lesions in Henoch-Schönlein purpura: a case report and review of the literature.
BMC Pediatr, 18 (2018), pp. 157

Study conducted at the Department of Dermatology, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.

Copyright © 2022. Sociedade Brasileira de Dermatologia
Download PDF
Idiomas
Anais Brasileiros de Dermatologia
Article options
Tools
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.